A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 698-705

  MacFarlane, Gordon ^a,e   Scheller, Dan ^a   Ersfeld, Diana ^a   Jensen, Todd ^a   Jevans, Anthony ^b   Wong, Pui Yeun ^c   Kobayashi, Masakazu ^d  

^a INCSTAR Corporation ^*  (United States)

^b JEWISH HOSPITAL   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ASTELLAS PHARMA INC   (Japan)

^e NONE   (United States)

Author keywords

FK506; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ORGANIC SOLVENT; TACROLIMUS;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 0029838033     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00012     Document Type: Article

References (28)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M. FK506, a novel immunosuppressant isolated from streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55.
2. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 1993;39:2219-28.
3. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991;23:2736-40.
4. Braun W, Kallen J, Mikol V, Walkinshaw MD, Wuthrich K. Three-dimensional structure and actions of immunosuppressants and their immunophilins. FASEB J 1995;9:63-72.
5. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell 1991;66:807-15.
6. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A. Proc Natl Acad Sci USA 1992;89:3686-90.
7. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991;352:803-7.
8. Banerji SS, Parsons JN, Tocci MJ. The immunosuppressant FK506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol 1991;11:4074-87.
9. Eidelman BH, Abu-Elmagd K, Wilson J. Neurologic complications of FK506. Transplant Proc 1991;23:3175-8.
10. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1310-5.
11. Fung JJ, Alessiani M, Abu-Elmagd K. Adverse effects associated with the use of FK506. Transplant Proc 1991;23:3105-8.
12. Fung JJ, Abu-Elmagd K, Jain A. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991;23:2977-83.
13. Sattler M, Guengerich FP, Yun C, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos Biol Fate Chem 1992;20:753-61.
14. Kobayashi M, Tamura K, Katayama N, et al. FK506 assay past and present: characteristics of FK506 ELISA. Transplant Proc 1991; 23:2725-9
15. Winkler M, Christians U, Stoll K, Baumann J, Pichlmayr R. Comparison of different assays for the quantitation of FK506 levels in blood or plasma. Ther Drug Monit 1994;16:281-6.
16. Christians U, Braun F, Kosian N, et al. High performance liquid chromatography/mass spectrometry of FK506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc 1991;23:2741-4.
17. Christians U, Braun F, Schmidt M, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft patients. Clin Chem 1992;38:2025-32.
18. D'Ambrosio R, Jusko WJ, Stabler T, Kobayashi M. Improved procedures for enzyme immunoassay of tacrolimus (FK506) in whole blood. Clin Chem 1994;40:159-60.
19. Wallemacq PE, Firdaous I, Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem 1993;39:1045-9.
20. Jusko WJ, D'Ambrosio R. Monitoring FK506 concentrations in plasma and whole blood. Transplant Proc 1991;23:2732-5.
21. Smith M. Method evaluation. In: Wild D, ed. The immunoassay handbook. New York: Stockton Press, 1994:256-62.
22. Winkler M, Baumann J, Ringe B, Loss M, Wonigeit K, Pichlmayr R. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994; 40:2247-53.
23. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995;17:606-14.
24. McMaster P, Mirza DF, Ismail T, Vennarecci G, Patapis P, Mayer AD. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-5.
25. Maciel RJ. Standard curve fitting in immunodiagnostics: a primer. J Clin Immunoassay 1985;8:98-106.
26. Christians U, Kruse R, Kownatzki R, et al. Measurement of FK506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991;23:940-1.
27. Iwasaki, K, Shiraga T, Matsuda H, Nagase K. Identification and biological activities of the metabolites oxidised at multiple sites of FK506. Drug Metab Dispos Biol Fate Chem 1995;23:28-34.
28. Brunet M, Pou L, Velasco R, et al. Comparative analysis of tacrolimus in whole blood by ProTrac ELISA and MEIA IMx methods [abstract 59]. Ther Drug Monit 1995;17:398.